G2G Bio FY 2025 Annual ReportBeta
G2G Bio annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 18, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
G2G Bio FY 2025 Annual Report Analysis
Business Overview
- • Revenue mix 2025: 64.8% from joint development/research services, 35.2% from licensing including GB-5001 for dementia
- • New second GMP plant construction scheduled for completion in 2027, with expected investment of KRW 80B for global GMP standards
Management Discussion & Analysis
- • Revenue KRW 423M (-45.0% YoY), operating loss KRW 12.2B (-13.4%), net loss KRW 12.1B (-85.5%) for fiscal year 2025
- • Major revenue decline due to joint R&D schedule adjustment and CDO contract timing changes, expecting expansion from fiscal 2026
Risk Factors
- • FX exposure sensitivity KRW ±28.6M for 10% USD move in FY2025, down from KRW ±52.1M in FY2024
- • Financial liabilities due within 1 year KRW 3,400M in FY2025 vs KRW 108,679M in FY2024, reflecting large decrease in short-term debt
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding